Drug intelligence / Profile preview

anti-DCLK1 siRNA

Development stage: Preclinical
Lead developer: University of Oklahoma
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intraperitoneal

Overview

anti-DCLK1 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of Doublecortin-like Kinase 1 (DCLK1), a microtubule-associated protein and a well-characterized tumor stem cell (TSC) marker. DCLK1 is overexpressed in various cancers, including pancreatic, colorectal, breast, renal, and liver cancers, where it regulates key oncogenic pathways, pluripotency factors, and epithelial-mesenchymal transition (EMT) promoting metastasis and drug resistance. Silencing DCLK1 via siRNA-mediated knockdown inhibits tumor cell self-renewal, migration, invasion, and tumor growth, while sensitizing cancer cells to chemotherapy and targeted therapies. Preclinical development of DCLK1-targeting siRNA therapeutics, such as nanoparticle-formulated delivery systems, has been pursued by COARE Biotechnology in collaboration with academic institutions.

Other names: DCLK1 siRNADCLK-1 siRNADCLK 1 siRNAdoublecortin-like kinase 1 siRNAsi-DCLK1si-DCLK-1si-DCLK 1siDCLK1siDCLK-1siDCLK 1

Targets

DCLK1 (Doublecortin-like kinase 1)

Beyond the preview

Go deeper on anti-DCLK1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-DCLK1 siRNA.

Explore the full profile